Inspire tumbles as TIGER-2 fails in cystic fibrosis
This article was originally published in Scrip
Executive Summary
"Disappointing and unexpected" results from Inspire Pharmaceuticals' second Phase III trial of cystic fibrosis drug candidate denufosol tetrasodium sent the US firm's share tumbling by almost 60% to close at $3.47 on 3 January.